GTCR, a Chicago-based private equity firm, has entered into definitive agreements to acquire generic drugmaker Zentiva from Advent International in a transaction valued at €4.1 billion (~₹36,600 crore).

JSA Advocates & Solicitors advised Zentiva on the Indian aspect of this transaction.

The transaction was led by Sidharrth Shankar (Partner), with support from Prakriti Jaiswal (Partner), Dhruv Malhotra (Partner) and Eksha Narayan.

White & Case advised Zentiva on this transaction.

The transaction team was led by partner Helen Croke (London) and included partners Vaclav Kubr (Prague), Jessica Kemp, Michael Evans and Annika Randhawa (London) and Sara Nordin (Brussels), local partner Dominik Stier (Frankfurt) and associates Trishala Naidu, Kikelomo Lawal, Ashwini Mohan, Amy Detheridge, Aliya Manji, Alice Parsons and Emma Middleton (London).

Zentiva is a leading pharmaceutical company focused on developing and manufacturing high-quality, affordable medicines, serving over 100 million people across more than 30 countries. In India, Zentiva operates a manufacturing facility in Ankleshwar, Gujarat.

GTCR brings deep sector expertise across multiple industries, including Financial Services & Technology, Healthcare, Technology, Media & Telecommunications, and Growth Business Services.

If you would like your Deals, Columns, Press Releases to be published on Bar & Bench, please fill in the form available here.